GlassScriptPhysician profile
Anshul Das
NPI 1518522655
$5,353.22
in general payments reported to CMS, 2019-2025
20 companies · $1,866 in 2025
The $1,866 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $306 · 2022: $284 · 2023: $865 · 2024: $1,912 · 2025: $1,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,423 · Travel and Lodging: $999 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,423.45 |
| Travel and Lodging | $998.61 |
| Education | $222.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,983.13 | 2024-2025 | Onyx Frontier, Hawkone, Turbohawk |
| Philips North America LLC | $911.83 | 2024-2025 | Igt Devices Undivided, (Bh4) Igt Devices Undivided |
| Boston Scientific Corporation | $497.50 | 2022-2024 | Watchman Flx, Stingray |
| Amgen INC. | $382.04 | 2021-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $373.34 | 2019-2023 | Farxiga |
| Chiesi USA, INC. | $226.11 | 2024 | Kengreal |
| Janssen Pharmaceuticals, INC | $189.90 | 2022-2023 | Xarelto |
| Abbott Laboratories | $184.56 | 2024 | Navitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $176.99 | 2021-2025 | Lifevest |
| Atricure, INC. | $118.33 | 2023 | |
| Shockwave Medical, INC | $64.04 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kestra Medical Technology Services, INC. | $60.20 | 2024 | Assure Wcd |
| Edwards Lifesciences Corporation | $40.14 | 2025 | Sapien 3 Ultra Resilia |
| Biogen, INC. | $28.13 | 2024 | Spinraza |
| Actelion Pharmaceuticals US, INC. | $28.00 | 2023 | Uptravi, Opsumit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.98 | 2025 | |
| Alvogen INC | $19.36 | 2022 | |
| Pfizer INC. | $16.50 | 2021 | |
| Merck Sharp & Dohme LLC | $13.58 | 2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $13.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anshul Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.